- Home
- RGNX vs CYRX Comparison
RGNX vs CYRX Comparison
Compare RGNX & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- CYRX
- Stock Information
- Founded
- RGNX 2008
- CYRX 1999
- Country
- RGNX United States
- CYRX United States
- Employees
- RGNX N/A
- CYRX N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- CYRX Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- CYRX Health Care
- Exchange
- RGNX Nasdaq
- CYRX Nasdaq
- Market Cap
- RGNX 424.8M
- CYRX 365.5M
- IPO Year
- RGNX 2015
- CYRX N/A
- Fundamental
- Price
- RGNX $8.17
- CYRX $8.75
- Analyst Decision
- RGNX Strong Buy
- CYRX Buy
- Analyst Count
- RGNX 8
- CYRX 11
- Target Price
- RGNX $31.75
- CYRX $11.36
- AVG Volume (30 Days)
- RGNX 542.3K
- CYRX 904.3K
- Earning Date
- RGNX 08-07-2025
- CYRX 08-05-2025
- Dividend Yield
- RGNX N/A
- CYRX N/A
- EPS Growth
- RGNX N/A
- CYRX N/A
- EPS
- RGNX N/A
- CYRX 1.35
- Revenue
- RGNX $156,718,000.00
- CYRX $237,879,000.00
- Revenue This Year
- RGNX $327.08
- CYRX N/A
- Revenue Next Year
- RGNX N/A
- CYRX $9.36
- P/E Ratio
- RGNX N/A
- CYRX $6.47
- Revenue Growth
- RGNX 80.70
- CYRX 14.20
- 52 Week Low
- RGNX $5.04
- CYRX $4.58
- 52 Week High
- RGNX $13.48
- CYRX $9.66
- Technical
- Relative Strength Index (RSI)
- RGNX 45.17
- CYRX 65.62
- Support Level
- RGNX $8.27
- CYRX $6.69
- Resistance Level
- RGNX $9.32
- CYRX $7.89
- Average True Range (ATR)
- RGNX 0.49
- CYRX 0.51
- MACD
- RGNX -0.04
- CYRX 0.01
- Stochastic Oscillator
- RGNX 20.16
- CYRX 77.44
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.